Stay updated on PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial
Sign up to get notified when there's something new on the PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial page.

Latest updates to the PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe study record now presents details of the completed pembrolizumab-versus-chemotherapy trial, including participant criteria, treatment arms, outcome measures, record dates, and a related publication. The previous access-denied error and NIH transition notice are no longer shown.SummaryDifference61%

- Check17 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide banner announces NIH’s transition to using “Super Intelligence” instead of “Artificial Intelligence” and links to related updates and FAQs.SummaryDifference1%

- Check31 days agoChange DetectedThe website footer revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer revision identifier was updated from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check59 days agoChange DetectedThe page now renders a 403 Forbidden error with the site header and footer visible, replacing the previously accessible study content and related documents.SummaryDifference20%

Stay in the know with updates to PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial page.